Therapeutic Translation of Epicardial Adipose Tissue Targeting in Heart Failure With Preserved Ejection Fraction: How Far Are We?
Open Access
- 4 August 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Abstract
Heart failure with preserved ejection fraction (HFpEF) exhibits an inflammatory‐metabolic phenotype in association with multiple factors. Among them, epicardial adipose tissue (EAT), a type of visceral adipose tissue surrounding the heart, has been gaining attention. EAT expansion is associated with the development of HFpEF, the increased risk for heart failure–related mortality in patients with HFpEF, independent of age, body mass index, diabetes, and sex. Thus, reducing EAT expansion has been proposed as a promising therapeutic strategy for treating HFpEF. Although specific treatment for EAT expansion is unavailable, modulating the inflammatory response and systemic energy metabolism are beneficial in improving clinical symptoms or prognosis in patients with HFpEF. To further enhance our capacity in effectively treating HFpEF, this review discusses the knowledge gaps between EAT expansion and the lack of a platform to reduce EAT expansion in HFpEF, including the choices of appropriate animal models, the conceptual mechanisms of glucose and lipid metabolism in EAT expansion toward potential strategies for selective EAT‐targeted therapeutic avenues.Keywords
This publication has 98 references indexed in Scilit:
- Epicardial, Visceral and Subcutaneous Adipose Tissue in Heart Failure with Preserved Ejection FractionESC Heart Failure, 2025
- Landscape of Glycolytic Metabolites and Their Regulating Proteins in Myocardium from Human Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2024
- Cardiovascular Significance and Genetics of Epicardial and Pericardial AdiposityJAMA Cardiology, 2024
- Impact of Epicardial Adipose Tissue on Cardiac Function and Morphology in Patients with Diastolic DysfunctionESC Heart Failure, 2024
- Epicardial Adipose Tissue and Pericardial Constraint in Heart Failure with Preserved Ejection FractionESC Heart Failure, 2024
- Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF studyEuropean Journal of Heart Failure, 2022
- Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fractionEuropean Journal of Heart Failure, 2022
- Diagnostic and Prognostic Implications of Heart Failure with Preserved Ejection Fraction Scoring SystemsESC Heart Failure, 2021
- Sex Differences in Cardiac Function, Biomarkers and Exercise Performance in Heart Failure with Preserved Ejection Fraction: Findings from the RELAX TrialEuropean Journal of Heart Failure, 2019
- Epicardial Fat in Heart Failure Patients with Mid-Range and Preserved Ejection FractionEuropean Journal of Heart Failure, 2018